Cetp inhibition 25 items
Obicetrapib and the class effect on Lp(a).
Trials, agents, guidance
Studies
- What existing lipid-lowering drugs do to Lp(a): meta-analysis of 147 RCTs (Xie et al., Atherosclerosis 2025)
- Obicetrapib lowers Lp(a) by 37 percent (15 nmol/L) in high-risk patients: pooled analysis (Nicholls et al., EHJ 2026)
- Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis
- Evacetrapib cuts Lp(a) by up to 40% alone and small LDL particles by up to 95%, a randomised trial of 393 patients (J Clin Lipidol 2016)
- Seven investigational agents, from siRNAs to a gene-editing candidate and a repurposed CETP inhibitor, now target Lp(a) in clinical trials, review finds (Curr Cardiovasc Risk Rep 2025)
- Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial
- Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial
- Diabetes lowers Lp(a) but raises PCSK9, and CETP inhibition with torcetrapib cuts Lp(a) by 11.1%, a clinical trial analysis (J Clin Lipidol 2018)
- CETP inhibitor anacetrapib lowers Lp(a) by cutting its production 41%, a kinetic trial of 39 patients (Arterioscler Thromb Vasc Biol 2017)
- Statins raise Lp(a) while PCSK9 and CETP inhibitors lower it, review of current and emerging therapies (Eur Cardiol 2026)
- Lp(a) biology and the full emerging-therapy pipeline, review spanning ASOs to CRISPR and obicetrapib (Cardiovasc Drugs Ther 2026)
- Apheresis cuts Lp(a) by 75% and the CETP inhibitor obicetrapib by 40%, but a 100 mg/dL reduction is needed to match LDL-C's mortality benefit, review calculates (Nutr Metab Cardiovasc Dis 2025)
- Traditional Lp(a) drugs barely reach 50% reduction while new RNA-interfering agents may exceed 95%, a review of emerging pharmacotherapies (Int J Mol Sci 2023)
- PCSK9 inhibitors and apheresis are the only current Lp(a)-lowering options proven to also cut cardiovascular risk, while ASOs and siRNAs may exceed 70% reduction, a review (Atherosclerosis 2022)
- Antisense drug AKCEA-APO(a)-LRx cuts Lp(a) by up to 80% as a phase 3 outcomes trial is planned, a review of antisense oligonucleotides for Lp(a) (Curr Atheroscler Rep 2019)
- Apheresis lowers Lp(a) by over 60%, while a phase 1 antisense drug reaches 88.8%, a review of Lp(a)-lowering options (Atheroscler Suppl 2017)
- Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis
- Statins, fibrates and bile acid sequestrants fail to lower Lp(a), leaving newer ASOs, CETP and PCSK9 inhibitors as the most effective options, a review (Am J Cardiovasc Drugs 2021)
- PCSK9 inhibitors are the only current lipid drugs that both lower Lp(a) and reduce cardiovascular events, while niacin and CETP inhibitors fall short, a review (Vasc Health Risk Manag 2021)
- Lp(a) is genetically fixed and diet-resistant, a review of its biology and response to statins, apheresis, PCSK9 and CETP inhibitors and antisense drugs (J Mol Cell Cardiol 2019)
- New drugs like apoB antisense, MTP and CETP inhibitors could finally test whether lowering Lp(a) helps, a review on when to measure Lp(a) (Eur Heart J 2013)